Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05368883
Other study ID # Cerrahpasa University
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date August 1, 2024

Study information

Verified date February 2024
Source Istanbul University - Cerrahpasa (IUC)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pulmonary rehabilitation is a key element in the management of people with chronic respiratory disease. A properly followed supervised physical training program in sarcoidosis is safe and has no absolute contraindications. Fatigue can also be associated with sarcoidosis for different reasons. Individualized rehabilitation training can improve the symptoms of patients with sarcoidosis. There is no study in the literature investigating the effectiveness of one-legged exercises that reduce peripheral muscle use, in patients with sarcoidosis. In our study, these two exercise methods will be compared by applying one-legged exercise training and two-legged exercise training. The effect of one-legged exercise training on exercise capacity and fatigue in sarcoidosis patients will be examined. The primary aim of our study is to compare the effects of one-legged exercise training, which is a current exercise approach, and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis. The secondary aim is to examine the effect of this exercise training on peripheral muscle strength and quality of life parameters.


Description:

Pulmonary rehabilitation is a key element in the management of individuals with chronic respiratory disease. A properly followed supervised physical training program in sarcoidosis is safe and has no absolute contraindications. Fatigue may be associated with different causes in sarcoidosis. Individualized rehabilitation practices can improve the symptoms of patients with sarcoidosis. There is no study in the literature investigating the effectiveness of one-legged exercises that reduce peripheral muscle use in patients with sarcoidosis. In our study, these two exercise methods will be compared by applying one-legged exercise training and two-legged exercise training. 26 patients will be randomly divided into 2 groups (n1=n2=13). While one group will receive one-legged cycling ergometer training, the other group will receive two-legged cycling ergometer training. After 8 weeks of exercise training, patients will be evaluated with, Pulmonary Function Test, Six-Minute Walk Test, Endurance Shuttle Walk test, Fatigue Assessment Scale, Multidimensional Fatigue Inventory, Blood Lactate Level (with lactate device), Medical Research Council Dyspnea Scale, Handheld dynamometer, St. George's Respiratory Questionnaire. The effect of one-legged exercise training on exercise capacity and fatigue in sarcoidosis patients will be examined. The primary aim of our study is to compare the effects of one-legged exercise training, which is a current exercise approach, and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis. The secondary aim is to examine the effect of this exercise training on peripheral muscle strength and quality of life parameters. The completion of the study will contribute to the determination of the content of the exercise programs to be applied in sarcoidosis patients and will reveal the effectiveness of one-legged exercise training, which is a current exercise method, in sarcoidosis patients.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 26
Est. completion date August 1, 2024
Est. primary completion date April 21, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - According to chest X-ray findings, the severity of the disease is to be stage 2,3,4 - Reaching a score of = 22 on the fatigue assessment scale - To be clinically stable. - No change in medical treatment. Exclusion Criteria: - Having an orthopedic, neurological, cardiac, or metabolic condition that may prevent participation and continuation of the exercise program throughout the study.

Study Design


Intervention

Other:
Exercise- One-Legged
One-legged cycling ergometer training will consist of 5 minutes of warm-up, 10 minutes for each leg in the first 2 weeks, 15 minutes of cycling training in the following weeks (5-10 minutes of rest while switching from one leg to the other leg) and a 5 minutes cool-down period. In the one-legged cycling ergometer training, it will be determined randomly that the patients start the exercise with the dominant or non-dominant leg. One-legged and two-legged exercise training will be maintained at moderate intensity (64-76%) according to maximum heart rate. Both groups will be given walking on flat ground once a week, with an exercise intensity of 11-13 according to the Borg scale, as home exercise.
Exercise-Two-Legged
Two-legged cycling ergometer training will consist of 5 minutes of warm-up, 20 minutes for the first 2 weeks, 30 minutes of cycling training in the following weeks, and a 5 minutes cool-down period. One-legged and two-legged exercise training will be maintained at moderate intensity (64-76%) according to maximum heart rate. Both groups will be given walking on flat ground once a week, with an exercise intensity of 11-13 according to the Borg scale, as home exercise.

Locations

Country Name City State
Turkey Istanbul University Cerrahpasa Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Istanbul University - Cerrahpasa (IUC)

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Other Dyspnoea Change of Medical Research Council Scale results from baseline to 8 weeks. The Medical Research Council Scale (MRCS) is a five-item scale based on various physical activities that produce dyspnea. Here, patients are asked to mark the level of activity that causes dyspnea in themselves. On the scale, 0 describes the best 4 dyspnea and the worst. 8 weeks
Other Muscle strength A hand-held dynamometer will be used to evaluate muscle strength. Muscle strength will be evaluated in the following muscles, each measurement will be made three times and the average will be taken.
M. Quadriceps Femoris, M. Tibialis Anterior, and M. Gastrosoleus
8 weeks
Other Health Related Quality of Life Change of Saint George Respiratory Questionnaire Results from baseline to 8 weeks.It is a self-answered questionnaire consisting of three categories, evaluating the symptoms, activities and effects of patients on daily life. It was developed in order to determine the severity of the disease as more comprehensive and sensitive. Symptoms examined; cough, sputum, wheezing and shortness of breath. Physical functions, housework and hobbies are questioned to determine activity status. The survey consists of 76 questions and is completed in 20 minutes. 0 indicates excellent health and 100 indicates worst healt 8 weeks
Other The Leicester Cough Questionnaire (LCQ) Change of The Leicester Cough Questionnaire (LCQ) Results from baseline to 8 weeks. The Leicester Cough Questionnaire (LCQ) is a HRQoL questionnaire validated for assessing chronic cough. It is a 19-item, self-completed questionnaire exploring the impact of cough severity across three domains: physical (eight items), psychological (seven items) and social (four items). The total severity score ranges from 3 to 21, with a lower score indicating greater impairment of health status due to cough. 8 weeks
Primary Change of Six-Minute Walking Test Distance from baseline to 8 weeks The distance covered in meters in a straight corridor of 30 meters will be recorded as fast as possible but without running for 6 minutes. The distance that normal individuals should take in this period is 400-700 meters. In addition, oxygen saturation and heart rate, resting fatigue and dyspnea levels will be evaluated with pulse oximetry before and after testing. Modified Borg Dyspnea and Fatigue Scales will be used to determine resting dyspnea and fatigue levels. 8 weeks
Primary Change of Endurance Shuttle Walking Test Distance from baseline to 8 weeks Endurance Shuttle Walk test: This is a standardized field test for the assessment of endurance capacity. In the Endurance Shuttle Walk Test, the participant walks at a constant speed between cones spaced 10 m apart. The selected speed is 85% of the participant's maximum capacity measured in the shuttle walk test at increasing speed. Therefore, before this test, the patient should be given an increasing speed incremental shuttle walk test. 8 weeks
Primary Incremental Shuttle Walk Test The incremental shuttle walk test (ISWT) is a field-based assessment of cardiorespiratory fitness and physical function. The ISWT is a performance-based assessment of exercise and functional capacity that measures walking distance in meters. It is a relatively brief and easy test to perform. The ISWT simulates a maximal cardiopulmonary test in a field setting and requires minimal equipment. Longer walking distances signify better performance. 8 weeks
Secondary Change of Fatigue Assessment Scale results from baseline to 8 weeks Fatigue Assessment Scale: It was planned to use Fatigue Assessment Scale to evaluate subjective fatigue. The Fatigue Assessment Scale is a subjective fatigue questionnaire consisting of 10 items. It includes five-point Likert type options (1=Always-5=Never). Higher scores indicate greater levels of fatigue. 8 weeks
Secondary Change of Multidimensional Fatigue Inventory results from baseline to 8 weeks Multidimensional Fatigue Inventory: It is used for the multidimensional evaluation of fatigue. It contains 20 questions containing different dimensions of fatigue. It consists of 5-point Likert-type questions. High scores indicate high fatigue. 8 weeks
Secondary Change of Blood Lactate Level from baseline to 8 weeks Blood Lactate Level: Blood lactate level measurements, which are an objective outcome measure in the evaluation of fatigue, will be made, in the 1st week and 8th week, before the exercise, immediately after the exercise, at the 5th minute after the exercise, and at the 20th minute after the exercise. 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT04064242 - Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis Phase 2
Terminated NCT00262132 - Mycophenolate for Pulmonary Sarcoidosis Phase 3
Recruiting NCT05415137 - Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis Phase 3
Recruiting NCT00001532 - Role of Genetic Factors in the Development of Lung Disease
Completed NCT04318392 - Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
Active, not recruiting NCT03755245 - Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis N/A
Completed NCT01587001 - The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis N/A
Recruiting NCT05890729 - A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Phase 1/Phase 2
Recruiting NCT02824419 - Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Phase 2/Phase 3
Recruiting NCT06205121 - Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis Phase 2
Completed NCT02200146 - Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). Phase 3
Terminated NCT01732211 - A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis Phase 2
Enrolling by invitation NCT06169397 - An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Phase 2
Not yet recruiting NCT05247554 - Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis Phase 3
Completed NCT03599414 - CASPA: CArdiac Sarcoidosis in PApworth
Recruiting NCT02188017 - Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) Phase 4
Recruiting NCT06113991 - Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
Completed NCT01169038 - Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis Phase 1
Completed NCT00701207 - Study of Nicotine Patches in Patients With Sarcoidosis Early Phase 1
Completed NCT03824392 - Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis Phase 1/Phase 2